SIGN UP
LOG IN
MARKET
CANF
CANF
Can Fite Biophar
AMEX
1.970
+0.010
+0.51%
Closed 15:57 04/18 EDT
OPEN
2.000
PREV CLOSE
1.960
HIGH
2.070
LOW
1.960
VOLUME
10.46K
TURNOVER
0
52 WEEK HIGH
3.330
52 WEEK LOW
1.520
MARKET CAP
9.83M
P/E (TTM)
-1.0996
1D
5D
1M
3M
1Y
5Y
Can-Fite’s Namodenoson Shows Promise for Liver Cancer
TipRanks · 3d ago
Can-Fite's Namodenoson Featured in Biomedicines for Liver Cancer and MASH Treatment Insights
Can-Fite BioPharma Ltd. Is a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases. Namodenoson is being evaluated in a Phase III study for advanced liver cancer. The journal Biomedicines published an article on the drug's anti-cancer activity and liver protective effects.
Benzinga · 3d ago
Weekly Report: what happened at CANF last week (0408-0412)?
Weekly Report · 3d ago
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
Can-Fite BioPharma Ltd. Is advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases. Namodenoson is being evaluated for treatment of liver cancer and metabolic dysfunction-associated steatohepatitis. The drug has been granted Orphan Drug Designation in the U.S. And Europe.
Barchart · 3d ago
Weekly Report: what happened at CANF last week (0401-0405)?
Weekly Report · 04/08 09:35
Can-Fite Advances MASH Treatment into Phase IIb
TipRanks · 04/03 11:59
Can-Fite BioPharma Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
Can-Fite BioPharma Ltd. Announced submission of an investigational new drug application to the U.S. Food and Drug Administration for the treatment of metabolic dysfunction-associated steatohepatitis. The company is advancing a pipeline of small molecule drugs that address oncological and inflammatory diseases.
Benzinga · 04/03 11:03
BUZZ-U.S. STOCKS ON THE MOVE-Eiger BioPharmaceuticals, Reddit, US energy sector
Stronger-than-expected manufacturing data propped up Treasury yields and tempered expectations of a rate cut in June. The Dow Jones Industrial Average was down 0.75% in midday trading on Monday. The top three S&P 500 percentage gainers were Micron Technology, Wynn Resorts.
Reuters · 04/01 17:47
About CANF
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Webull offers Can Fite Biopharma Ltd stock information, including AMEX: CANF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CANF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading CANF stock methods without spending real money on the virtual paper trading platform.